Alveolar soft part sarcoma
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
3 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
Atezolizumab monotherapy
Regimen variant #1, q3wk
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Chen et al. 2023 (Study ML39345) | 2017-04 to 2022-07 | Phase 2 (RT) |
Immunotherapy
- Atezolizumab (Tecentriq) by the following age-based criteria:
- 18 years old or older: 1200 mg IV once on day 1
- Younger than 18 years old: 15 mg/kg (maximum dose of 1200 mg) IV once on day 1
21-day cycles
Regimen variant #2, q2wk
| FDA-recommended dose |
Regimen variant #3, q4wk
| FDA-recommended dose |
References
- Study ML39345: Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023 Sep 7;389(10):911-921. link to original article contains dosing details in abstract PubMed NCT03141684